133 related articles for article (PubMed ID: 38214418)
1. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759.
Pujalte-Martin M; Belaïd A; Bost S; Kahi M; Peraldi P; Rouleau M; Mazure NM; Bost F
Mol Oncol; 2024 Jan; ():. PubMed ID: 38214418
[TBL] [Abstract][Full Text] [Related]
2. OXPHOS-targeting drugs in oncology: new perspectives.
Kalyanaraman B; Cheng G; Hardy M; You M
Expert Opin Ther Targets; 2023; 27(10):939-952. PubMed ID: 37736880
[TBL] [Abstract][Full Text] [Related]
3. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells.
Vangapandu HV; Alston B; Morse J; Ayres ML; Wierda WG; Keating MJ; Marszalek JR; Gandhi V
Oncotarget; 2018 May; 9(38):24980-24991. PubMed ID: 29861847
[TBL] [Abstract][Full Text] [Related]
4. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.
Whitaker-Menezes D; Martinez-Outschoorn UE; Flomenberg N; Birbe RC; Witkiewicz AK; Howell A; Pavlides S; Tsirigos A; Ertel A; Pestell RG; Broda P; Minetti C; Lisanti MP; Sotgia F
Cell Cycle; 2011 Dec; 10(23):4047-64. PubMed ID: 22134189
[TBL] [Abstract][Full Text] [Related]
5. An inhibitor of oxidative phosphorylation exploits cancer vulnerability.
Molina JR; Sun Y; Protopopova M; Gera S; Bandi M; Bristow C; McAfoos T; Morlacchi P; Ackroyd J; Agip AA; Al-Atrash G; Asara J; Bardenhagen J; Carrillo CC; Carroll C; Chang E; Ciurea S; Cross JB; Czako B; Deem A; Daver N; de Groot JF; Dong JW; Feng N; Gao G; Gay J; Do MG; Greer J; Giuliani V; Han J; Han L; Henry VK; Hirst J; Huang S; Jiang Y; Kang Z; Khor T; Konoplev S; Lin YH; Liu G; Lodi A; Lofton T; Ma H; Mahendra M; Matre P; Mullinax R; Peoples M; Petrocchi A; Rodriguez-Canale J; Serreli R; Shi T; Smith M; Tabe Y; Theroff J; Tiziani S; Xu Q; Zhang Q; Muller F; DePinho RA; Toniatti C; Draetta GF; Heffernan TP; Konopleva M; Jones P; Di Francesco ME; Marszalek JR
Nat Med; 2018 Jul; 24(7):1036-1046. PubMed ID: 29892070
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas.
de Groot E; Varghese S; Tan L; Knighton B; Sobieski M; Nguyen N; Park YS; Powell R; Lorenzi PL; Zheng B; Stephan C; Gopal YNV
Cancer Metab; 2022 Feb; 10(1):6. PubMed ID: 35193687
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [
Gammon ST; Pisaneschi F; Bandi ML; Smith MG; Sun Y; Rao Y; Muller F; Wong F; De Groot J; Ackroyd J; Mawlawi O; Davies MA; Gopal YNV; Di Francesco ME; Marszalek JR; Dewhirst M; Piwnica-Worms D
Cells; 2019 Nov; 8(12):. PubMed ID: 31766580
[TBL] [Abstract][Full Text] [Related]
8. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation.
Liu F; Kalpage HA; Wang D; Edwards H; Hüttemann M; Ma J; Su Y; Carter J; Li X; Polin L; Kushner J; Dzinic SH; White K; Wang G; Taub JW; Ge Y
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847115
[TBL] [Abstract][Full Text] [Related]
9. Why Metformin Should Not Be Used as an Oxidative Phosphorylation Inhibitor in Cancer Patients.
Sakellakis M
Chemotherapy; 2023; 68(4):185-189. PubMed ID: 37343530
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Targeting of Tumor Cells and Tumor Immune Microenvironment Vulnerabilities.
Kalyanaraman B; Cheng G; Hardy M
Front Oncol; 2022; 12():816504. PubMed ID: 35756631
[TBL] [Abstract][Full Text] [Related]
11. Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer
Thakur S; Daley B; Gaskins K; Vasko VV; Boufraqech M; Patel D; Sourbier C; Reece J; Cheng SY; Kebebew E; Agarwal S; Klubo-Gwiezdzinska J
Clin Cancer Res; 2018 Aug; 24(16):4030-4043. PubMed ID: 29691295
[No Abstract] [Full Text] [Related]
12. Characterizing OXPHOS inhibitor-mediated alleviation of hypoxia using high-throughput live cell-imaging.
Beerkens APM; Boreel DF; Nathan JA; Neuzil J; Cheng G; Kalyanaraman B; Hardy M; Adema GJ; Heskamp S; Span PN; Bussink J
Cancer Metab; 2024 May; 12(1):13. PubMed ID: 38702787
[TBL] [Abstract][Full Text] [Related]
13. Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research.
Kalyanaraman B
FASEB J; 2022 Apr; 36(4):e22226. PubMed ID: 35233843
[TBL] [Abstract][Full Text] [Related]
14. Glibenclamide Mimics Metabolic Effects of Metformin in H9c2 Cells.
Salani B; Ravera S; Fabbi P; Garibaldi S; Passalacqua M; Brunelli C; Maggi D; Cordera R; Ameri P
Cell Physiol Biochem; 2017; 43(3):879-890. PubMed ID: 28954268
[TBL] [Abstract][Full Text] [Related]
15. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
[TBL] [Abstract][Full Text] [Related]
16. Targeting Metabolic Vulnerabilities to Overcome Prostate Cancer Resistance: Dual Therapy with Apalutamide and Complex I Inhibition.
Baumgartner V; Schaer D; Eberli D; Salemi S
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067315
[TBL] [Abstract][Full Text] [Related]
17. Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in
Feng J; Lian Z; Xia X; Lu Y; Hu K; Zhang Y; Liu Y; Hu L; Yuan K; Sun Z; Pang X
Acta Pharm Sin B; 2023 Mar; 13(3):1145-1163. PubMed ID: 36970205
[TBL] [Abstract][Full Text] [Related]
18. Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis.
Jin P; Jiang J; Zhou L; Huang Z; Qin S; Chen HN; Peng L; Zhang Z; Li B; Luo M; Zhang T; Ming H; Ding N; Li L; Xie N; Gao W; Zhang W; Nice EC; Wei Y; Huang C
EMBO Mol Med; 2022 Dec; 14(12):e16082. PubMed ID: 36321555
[TBL] [Abstract][Full Text] [Related]
19. Biguanide MC001, a Dual Inhibitor of OXPHOS and Glycolysis, Shows Enhanced Antitumor Activity Without Increasing Lactate Production.
Fu J; Liu S; Hu M; Liao X; Wang X; Xu Z; Li Q; Quan J
ChemMedChem; 2022 Mar; 17(6):e202100674. PubMed ID: 34984842
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin.
Sanchez-Alvarez R; Martinez-Outschoorn UE; Lamb R; Hulit J; Howell A; Gandara R; Sartini M; Rubin E; Lisanti MP; Sotgia F
Cell Cycle; 2013 Jan; 12(1):172-82. PubMed ID: 23257779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
